cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Article reviewing anticancer agent Onconase published in journal
October 25th, 2005
Alfacell Corporation (ACEL) announced that a new publication reviewing Onconase (ranpirnase), the company's lead investigational drug candidate, appears in the current edition of the journal Cancer Investigation. The publication, entitled, "Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase," describes Onconase as representing a "novel approach to mechanism-based cancer therapy," and states that the results of multiple tumor-specific trials have been interpreted as showing "clinical effectiveness in mesothelioma, breast cancer and non-small cell lung cancer." The publication also affirms that the...
Source: cancer weekly (2005-10-25)
|
